Genes & Cancer · 2011 · 1.8K citations · 59 references
Life SciencesCancer BiologyMolecular BiologyCell SignalingMolecular OncologySignal TransductionAngiogenesisAngiogenesis In CancerGrowth Factor SignalingVenom BiologyCell Proliferation StimulationLymphangiogenesisPhosphatidylinositol 3-Kinase-akt PathwayPi3k-akt Signaling PathwayVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor Signaling
VEGF and its receptors orchestrate both normal and disease‑associated angiogenesis, with VEGF‑A/VEGFR‑1/2 driving vascular growth and VEGF‑C/D/VEGFR‑3 mediating lymphangiogenesis, and VEGFR‑2 preferentially activating PLCγ‑PKC‑MAPK signaling. The authors propose exploiting the VEGF‑VEGFR system as a therapeutic target for anti‑angiogenic cancer treatment and for pro‑angiogenic interventions in neuronal degeneration and ischemic disease.
The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have been shown to play major roles not only in physiological but also in most pathological angiogenesis, such as cancer. VEGF belongs to the PDGF supergene family characterized by 8 conserved cysteines and functions as a homodimer structure. VEGF-A regulates angiogenesis and vascular permeability by activating 2 receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk1 in mice). On the other hand, VEGF-C/VEGF-D and their receptor, VEGFR-3 (Flt-4), mainly regulate lymphangiogenesis. The VEGF family includes other interesting variants, one of which is the virally encoded VEGF-E and another is specifically expressed in the venom of the habu snake (Trimeresurus flavoviridis). VEGFRs are distantly related to the PDGFR family; however, they are unique with respect to their structure and signaling system. Unlike members of the PDGFR family that strongly stimulate the PI3K-Akt pathway toward cell proliferation, VEGFR-2, the major signal transducer for angiogenesis, preferentially utilizes the PLCγ-PKC-MAPK pathway for signaling. The VEGF-VEGFR system is an important target for anti-angiogenic therapy in cancer and is also an attractive system for pro-angiogenic therapy in the treatment of neuronal degeneration and ischemic diseases.
59
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
David W. M. Leung, George Cachianes, Wun-Jing Kuang et al. · Science · 1989 · 5K citations
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Donald R. Senger, Stephen J. Galli, Ann M. Dvořàk et al. · Science · 1983 · 4K citations
Medicine, Biochemistry, Oncology +13
Sharon E. Maynard, Jiang-Yong Min, Jaime R. Merchan et al. · Journal of Clinical Investigation · 2003 · 4K citations · Full text